Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

e-cigarettes

- PMLiVE

NICE backtracks on Gazyvaro rejection

Roche agrees to patient access scheme to help gain leukaemia recommendation

- PMLiVE

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost

- PMLiVE

UK e-cigarette advert comes under fire

BMA accuses campaign of glamorising smoking

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

SMC fails to recommend Roche’s Perjeta

Says drug is not a cost-effective option in breast cancer

Roche - Basel

Roche invests in diagnostics in China

Commits 450m Swiss francs to manufacturing facility

Teva Pharma logo

Cuts help Teva raise profits, despite flat sales

Earnings attributed largely to firm’s generics business

- PMLiVE

Roche outlines $3bn expansion for its Basel site

Decade-long programme will see the Swiss pharma company boost its presence in its home city

- PMLiVE

Pressure put on Roche to cut Kadcyla’s UK price

30,000 people sign petition to help make the breast cancer drug available on the NHS

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

Teva Pharma logo

Teva scales back R&D as Copaxone competition looms

Copaxone accounts for almost 40% of its revenue

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links